Monday, February 26, 2024
Scenic Biotech is a biopharmaceutical company advancing modifier therapy, a radically new approach to treating genetic disorders. Instead of targeting the primary disease-causing mutation, modifier therapy seeks to rebalance health by inactivating another function in the genome, leading to protection from disease. Our robust pipeline features both wholly owned and partnered first-in-class treatments for genetic disorders, all rooted in modifier therapy. Our small molecule programs are derived from our proprietary Cell-seq™️ platform for target identification. Scenic Biotech is headquartered in Amsterdam, The Netherlands, with an additional office in New York City, New York.
CEO/Top Company Official
CA (Oscar) Izeboud
Lead Product in Development
SC-2882 in immuno-oncology, and NPC (a lysosomal storage disorder).
Development Phase of Primary Product
Number Of Unlicensed Products